Derek Wallace, Vice President and Dengue Global Program Lead at Takeda, discusses the first public presentation of long-term safety and efficacy results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate, TAK-003, and the launch of the company’s global HCP dengue education platform, Dengue Academy.
#Dengue #DengueVaccine
Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, Mr. Wallace leads the global program team in the development of Takeda’s dengue vaccine candidate (TAK-003). Mr. Wallace joined Takeda in September 2013 as Global Programme Medical Director responsible for the development of TAK-003 as well as Takeda’s enterovirus vaccine candidate.Mr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, Mr. Wallace held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur. At Sanofi, Mr. Wallace served as clinical team leader for Sanofi’s dengue vaccine candidate, influenza studies and preparations for first-in-human studies of vaccine candidates for malaria and meningitis B. His experience also includes transplant, cardiology and women’s health.Mr. Wallace holds a Diploma of Vaccinology from the Institut Pasteur and a Diploma in Pharmaceutical Medicine from University of Wales, Cardiff. He received his Bachelor of Medicine, Bachelor of Surgery from the University of Queensland.
